Velocity Fund Partners

Velocity Fund Partners is a private equity investment firm founded in 2016 and based in Pittsburgh, Pennsylvania. It focuses on opportunities in the life sciences and healthcare sectors, including pharmaceuticals, medical devices, diagnostics, and healthcare services. The firm seeks to back research programs or startup companies with a distinct scientific advantage and the potential to significantly advance the development of devices, drugs, diagnosis, or treatment. Its leadership combines experience from healthcare management and life sciences, supported by a team of professionals in operations and finance to evaluate and support growth initiatives.

Kenneth Melani MD

Managing Partner

3 past transactions

Scribenote

Seed Round in 2024
Scribenote is a technology company specializing in AI-driven medical scribe solutions for veterinarians. Its platform automates and simplifies the documentation process, reducing administrative tasks and allowing veterinarians to focus more on patient care. The system captures audio, generates transcripts, and creates SOAP notes during appointments, integrating seamlessly with practice management software. This streamlines workflows, enhances client experience, and improves overall efficiency in veterinary clinics.

MedMe Health

Seed Round in 2021
MedMe Health is a patient care platform for pharmacies that enables scheduling, delivery, and tracking of clinical services at scale, both virtually and on-site. The platform uses proprietary algorithms to identify applicable medical services and supports online scheduling, digital documentation, and automated follow-up appointments, helping pharmacies streamline workflows and expand patient care capabilities. By integrating scheduling, documentation, and clinical services, the solution supports pharmacist-led care, strengthens patient relationships, and diversifies revenue streams across virtual and in-person settings.

InClinica

Acquisition in 2016
InClinica, Inc. is a global contract research organization (CRO) that provides comprehensive clinical development and pharmaceutical research services to pharmaceutical, biotechnology, and medical device companies. Founded in 2007 and based in Wayne, Pennsylvania, the company specializes in various therapeutic areas, including oncology, metabolic diseases, inflammatory diseases, cardiovascular conditions, infectious diseases, gastroenterology, neuropsychiatry, pain management, rheumatology, women’s health, and ophthalmology. InClinica excels in all phases of clinical trials, particularly first-in-man and phase 2 studies, and operates internationally, with additional offices in Kuala Lumpur, Malaysia, the U.K., and Israel. The company offers expertise in site management, pharmacovigilance, and clinical research, helping clients navigate critical decisions in the development of their pharmaceutical assets. InClinica was previously known as IndiPharm Inc. until its rebranding in 2016.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.